Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status

Lumley SF. et al, (2022), Clinical Infectious Diseases, 74, 1208 - 1219

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ogbe A. et al, (2022), JCI Insight, 7

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei J. et al, (2022), Nature Medicine

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.

Costa Clemens SA. et al, (2022), Lancet (London, England)

An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease

Peng Y. et al, (2022), Nature Immunology, 23, 50 - 61

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Stuart ASV. et al, (2022), Lancet (London, England), 399, 36 - 49

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.

Dejnirattisai W. et al, (2021), Lancet (London, England)

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

Townsend A. et al, (2021), Nature Communications, 12

Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins

Renner M. et al, (2021), Nature Communications, 12

Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections

Eyre DW. et al, (2021), BMC Infectious Diseases, 21

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

Ogbe A. et al, (2021), Nature Communications, 12

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.

Liu C. et al, (2021), Cell host & microbe

Human antibody C10 neutralizes by diminishing Zika but enhancing dengue virus dynamics.

Lim X-X. et al, (2021), Cell

The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses.

Sharma A. et al, (2021), Cell

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Payne RP. et al, (2021), Cell, 184, 5699 - 5714.e11

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom

Wei J. et al, (2021), Nature Microbiology, 6, 1140 - 1149

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Flaxman A. et al, (2021), The Lancet, 398, 981 - 990

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?